logo
Plus   Neg
Share
Email

Agilent Launches Immunoassay Kit To Detect SARS-CoV-2 Antibodies

Agilent Technologies Inc. (A) said that it has launched its Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay or ELISA kit that is intended for the qualitative detection of immunoglobulin G or IgG antibodies to SARS-CoV-2 in human serum or plasma.

The kit, which marks Agilent's entrance into SARS-CoV-2 testing in the US, has completed the notification process to the FDA.

The company plans to register the assay in other markets in 2021 including Canada, Europe, and selected Asia Pacific and Latin American countries.

In clinical study, the SARS-CoV-2 IgG ELISA kit is a highly accurate immunoassay with 98.9% sensitivity and 98.8% specificity, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp's Mobileye and self-driving delivery startup Udelv have signed a deal to launch a fully driverless delivery service in the United States by 2023. The companies plan to produce more than 35,000 Mobileye-driven Transporters by 2028. Domino's Pizza and autonomous vehicle startup Nuro are launching autonomous pizza delivery in Houston, this week. Some Domino's customers in Houston can have a pizza delivered by Nuro's R2 robot. CVS Health is now offering cost COVID-19 vaccines at select CVS Pharmacy locations in four more U.S. states as part of its ongoing effort to expand access to COVID-19 vaccines. It has now expanded the program to 51 more select locations in Arkansas, Nebraska, Iowa and Maine. It began in Washington, West Virginia, Delaware and New Mexico at 15 select locations from March 31.
Follow RTT